| 摘要 |
1,273,897. Imidazo- and Pyrimido(2,1-6] quinazoline compounds. SMITH KLINE & FRENCH LABORATORIES. 16 Dec., 1970 [18 Dec., 1969], No. 59648/70. Heading C2C. Novel compounds of the Formulae I and II wherein R 1 is hydrogen, halogen, trifluoromethyl, C 1-4 alkyl, C 1-4 alkoxy, C 2-4 alkanoyl, sulphamoyl or hydroxy; R 2 is hydrogen, C 1-4 alkyl or C 2-4 alkanoyl; R 3 is C 1-4 alkyl or C 2-4 alkanoyl and n is 1 or 2 and pharmaceutically acceptable salts thereof may be prepared by reduction of the corresponding quinazolinone III with metallic hydride, alkalation or alkanoylating to introduce R 2 and R 3 , or introducing the group R 1 into the molecule. The intermediate quinazolinone III may be prepared by reacting an isatoic anhydride IV with a 2-alkylthio-2-imidazoline or a 2-alkylthio- 3,4,5,6-tetrahydropyrimidine or reacting an N- (3-chloropropyl)-2-chloro-4H-quinazolin - 4 - one with ammonia. The isatoic anhydride IV may be prepared by reacting an anthranilic acid with phosgene or oxidizing an isatin with chromium trioxide. The 5-w-butoxy-isatin may be prepared by cyclizing with sulphuric acid N-(p-n-butoxyphenyl)-α-hydroxyiminoacetamide which in turn is prepared by reacting p-n-butoxy-aniline with chloral hydrate and hydroxylamine hydrochloride. The intermediate N-(3-chloropropyl)-2,6-dichloro-4H-quinazolin-4-one may be prepared by reacting thionyl chloride and 2,6-dichloro-4-(3- hydroxypropoxy)-quinazoline, which in turn is prepared by reacting a 1,3-propanediol with a 2,4,6-trichloroquinazoline. Pharmaceutical compositions of the compounds I and II show pharmacodynamic activity and central nervous system depressant activity when administered with pharmaceutical carriers. |
